insulin-like growth factor-binding protein 7 (IGFBP7) & tissue inhibitor of metalloproteinase in urine (NephroCheck)
Jump to navigation
Jump to search
Indications
- predicts risk of acute renal failure
Clinical significance
- accuracy: 76-92%
- specificity: 0.5
Notes
- results available in 20 minutes (NephroCheck)
More general terms
References
- ↑ FDA News Release. Sept 5, 2014 FDA allows marketing of the first test to assess risk of developing acute kidney injury. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412910.htm